ICM6011: Brain and Mind, Disorders of Supraspinal Systems

Academic year 2015-2016





[1]

Arendt, T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization.

[2]

Arendt, T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization.

[3]

Bezard, E. et al. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies : Article : Nature Reviews Neuroscience.

[4]

Chen, K. et al. 2007. Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental Seizures. Journal of Neuroscience. 27, 1 (Jan. 2007), 46–58. DOI:https://doi.org/10.1523/JNEUROSCI.3966-06.2007.

[5]

Dackis, C. and O'Brien, C. Neurobiology of addiction: treatment and public policy ramifications : Article : Nature Neuroscience.

De Keyser, J. et al. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?

[7]

Dominguez, I.D. and Strooper, B.D. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease.

[8]

Fredrik Jarskog, L. et al. Schizophrenia: New Pathological Insights and Therapies - Annual Review of Medicine, 58(1):49.

[9]

Iritani, S. 2007. Neuropathology of schizophrenia: A mini review. Neuropathology. 27, 6 (Dec. 2007), 604–608. DOI:https://doi.org/10.1111/j.1440-1789.2007.00798.x.

[10]

Krisztina et al. The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus.

[11]

LARUELLE, M. et al. 2003. Glutamate, Dopamine, and Schizophrenia. Annals of the New York Academy of Sciences. 1003, 1 (Nov. 2003), 138–158. DOI:https://doi.org/10.1196/annals.1300.063.

[12]

Löscher, W. Current status and future directions in the pharmacotherapy of epilepsy.

[13]

Maalouf, M. et al. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies.

[14]

McMurray, C.T. Huntington's disease: new hope for therapeutics.

[15]

Mulley, J.C. et al. Channelopathies as a genetic cause of epilepsy.

[16]

Mulley, J.C. et al. Channelopathies as a genetic cause of epilepsy.

[17]

Nestler, E.J. Is there a common molecular pathway for addiction? : Article : Nature Neuroscience.

[18]

Nyilas, R. et al. Enzymatic Machinery for Endocannabinoid Biosynthesis Associated with Calcium Stores in Glutamatergic Axon Terminals.

[19]

Schmitz, B. et al. 2010. Assessing the unmet treatment need in partial-onset epilepsy: Looking beyond seizure control. Epilepsia. 51, 11 (Nov. 2010), 2231–2240. DOI:https://doi.org/10.1111/j.1528-1167.2010.02759.x.

[20]

Solinas, M. et al. 2009. The endocannabinoid system in brain reward processes. British Journal of Pharmacology. 154, 2 (Jan. 2009), 369–383. DOI:https://doi.org/10.1038/bjp.2008.130.

Sudhof, T. 6AD. The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature (London). (6AD).

[22]

Torrey, E.F. et al. 2005. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biological Psychiatry. 57, 3 (Feb. 2005), 252–260. DOI:https://doi.org/10.1016/j.biopsych.2004.10.019.

[23]

Volkow, N.D. et al. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies.

[24]

Zhu, H.L. et al. Iptakalim protects against hypoxic brain injury through multiple pathways associated with ATP-sensitive potassium channels.

[25]

The endocannabinoid system in brain reward processes.

[26]

The synaptic vesicle cycle: a cascade of protein-protein interactions.